There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Prostate biopsy is commonly performed for cancer detection and management. The benefits
and risks of prostate biopsy are germane to ongoing debates about prostate cancer
screening and treatment.
To perform a systematic review of complications from prostate biopsy.
A literature search was performed using PubMed and Embase, supplemented with additional
references. Articles were reviewed for data on the following complications: hematuria,
rectal bleeding, hematospermia, infection, pain, lower urinary tract symptoms (LUTS),
urinary retention, erectile dysfunction, and mortality.
After biopsy, hematuria and hematospermia are common but typically mild and self-limiting.
Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious
complications are increasing over time and are the most common reason for hospitalization
after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated
by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient
LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates
reported after transperineal template biopsy. Biopsy-related mortality is rare.
Preparation for biopsy should include antimicrobial prophylaxis and pain management.
Prostate biopsy is frequently associated with minor bleeding and urinary symptoms
that usually do not require intervention. Infectious complications can be serious,
requiring prompt management and continued work into preventative strategies.
Published by Elsevier B.V.
This paper on the fluoroquinolone resistance epidemiology stratifies the data according to the different prescription patterns by either primary or tertiary caregivers and by indication. Global surveillance studies demonstrate that fluoroquinolone resistance rates increased in the past years in almost all bacterial species except S. pneumoniae and H. influenzae, causing community-acquired respiratory tract infections. However, 10 to 30% of these isolates harbored first-step mutations conferring low level fluoroquinolone resistance. Fluoroquinolone resistance increased in Enterobacteriaceae causing community acquired or healthcare associated urinary tract infections and intraabdominal infections, exceeding 50% in some parts of the world, particularly in Asia. One to two-thirds of Enterobacteriaceae producing extended spectrum β-lactamases were fluoroquinolone resistant too. Furthermore, fluoroquinolones select for methicillin resistance in Staphylococci. Neisseria gonorrhoeae acquired fluoroquinolone resistance rapidly; actual resistance rates are highly variable and can be as high as almost 100%, particularly in Asia, whereas resistance rates in Europe and North America range from 30% in established sexual networks. In general, the continued increase in fluoroquinolone resistance affects patient management and necessitates changes in some guidelines, for example, treatment of urinary tract, intra-abdominal, skin and skin structure infections, and traveller's diarrhea, or even precludes the use in indications like sexually transmitted diseases and enteric fever.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.